How to reduce radiation-related toxicity in patients with cancer of the head and neck

被引：26

作者：

Garden A.S. ^{[1
]}

Lewin J.S. ^{[1
]}

Chambers M.S. ^{[1
]}

机构：

[1] Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

来源：

Current Oncology Reports | 2006年 / 8卷 / 2期

关键词：

Neck Cancer; Radiat Oncol Biol Phys; Pilocarpine; Oral Mucositis; Radiation Therapy Oncology Group;

D O I：

10.1007/s11912-006-0049-x

中图分类号：

学科分类号：

摘要：

Radiation for head and neck cancers is often curative, but high doses are used. Normal tissues, including mucosa salivary glands, and muscles, are exposed to these high doses, resulting in severe mucositis, xerostomia, and dysphagia. Efforts to minimize toxicity have involved advances in radiation physics and development of pharmacologic agents. Radiation techniques include conformal and intensity-modulated therapy, which minimizes dose to normal tissues while delivering high doses to tumor targets. Drugs used to prevent mucositis have tareeted infection, but recently Interest has been shown in the use of growth factors. Cholinergic agonists and cytoprotective agents, specifically amifostine, can address xerostomia. Involvement of speech pathologists in evaluation and treatment of patients with dysphagia can minimize swallowing difficulties and identify the tissues most responsible for swallowing. Minimizing radiation dose to these tissues may lower the incidence of radiation-induced dysphagia. © 2006 by Current Science Inc.

引用

页码：140 / 145

页数：5

共 30 条

[1]

Bernier J., Domenge C., Ozsahin M., Et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N Engl J Med, 350, pp. 1945-1952, (2004)

[2]

Forastiere A.A., Goepfert H., Maor M., Et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer, N Engl J Med, 349, pp. 2091-2098, (2003)

[3]

Cooper J.S., Pajak T.F., Forastiere A.A., Et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck, N Engl J Med, 350, pp. 1937-1944, (2004)

[4]

Fu K.K., Pajak T.F., Trotti A., Et al., A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003, Int J Radiat Oncol Biol Phys, 48, pp. 7-16, (2000)

[5]

Trotti A., Bellm L.A., Epstein J.B., Et al., Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review, Radiother Oncol, 66, pp. 253-262, (2003)

[6]

Sonis S.T., The pathobiology of mucositis, Nat Rev Cancer, 4, pp. 277-284, (2004)

[7]

Trotti A., Garden A., Warde P., Et al., A multinational randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy, Int J Radiat Oncol Biol Phys, 58, pp. 674-681, (2004)

[8]

Donnelly J.P., Bellm L.A., Epstein J.B., Et al., Antimicrobial therapy to prevent or treat oral mucositis, Lancet Infect Dis, 3, pp. 405-412, (2003)

[9]

Spielberger R., Stiff P., Bensinger W., Et al., Palifermin for oral mucositis after intensive therapy for hematologic cancers, N Engl J Med, 351, pp. 2590-2598, (2004)

[10]

Brizel D.M., Le Q.T., Rosenthal D., Et al., Phase 2 study of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer treated with standard (SRT) or hyperfractionated irradiation (HRT) & concurrent chemotherapy, Int J Radiat Oncol Biol Phys, 54, SUPPL. 2, (2002)

← 1 2 3 →